[1]阎俪, 马雄. 胆汁淤积性肝病的治疗. 实用肝脏病杂志, 2016, 19(6):650-653. [2]顾静娴, 曲凯, 刘昌. UDCA治疗原发性胆汁性肝硬化临床疗效的Meta分析. 中华肝脏外科手术学电子杂志, 2017, 6(4):320-323. [3]Cheung AC, Lapointe‐Shaw L, Kowgier M, et al. Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes. Aliment Pharmacol Ther, 2016, 43(2):283-293. [4]奉白蕾, 俞慧宏, 沈薇. UDCA联合苯扎贝特治疗难治性原发性胆汁性胆管炎的Meta分析. 中华肝脏病杂志, 2019, 27(4):304-311. [5]Li Y, Tang R, Psc L, et al. Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases. Autoimmun Rev, 2017, 16(9):885-896. [6]European Association for the Study of the Liver. EASL clinical practice guidelines : management of cholestatic liver diseases. J Hepatol, 2009, 51(2):237-267. [7]Lindor KD, Gershwin ME, Poupon R, et al. Primary biliary cirrhosis. Hepatology, 2009, 50(1):291-308. [8]李艳梅, 王绮夏, 马雄. 原发性胆汁性胆管炎治疗进展. 中华肝脏病杂志, 2017, 25(11):805-809. [9]朱琳, 邢卉春. 肠道菌群与胆汁淤积性肝病. 中华肝脏病杂志, 2019, 27(5):325-329. [10]Zhang D, Hao XX, Xu LI, et al. Intestinal flora imbalance promotes alcohol-induced liver fibrosis by the TGFβ/smad signaling pathway in mice. Oncol Lett, 2017, 14(4):4511-4516. [11]Rust C, Sauter GH, Oswald M, et al. Effect of cholestyramine on bile acid pattern and synthesis during administration of ursodeoxycholic acid in man. Eur J Clin Invest, 2015, 30(2):135-139. [12]Nevens F, Andreone P, Mazzella G, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med, 2016, 375(7):631-643. [13]Nava-Ocampo AA, Suster S, Muriel P. Effect of colchiceine and ursodeoxycholic acid on hepatocyte and erythrocyte membranes and liver histology in experimentally induced carbon tetrachloride cirrhosis in rats. Eur J Clin Invest, 2015, 27(1):77-84. [14]Burman BE, Jhaveri MA, Kowdley KV. An update on the treatment and follow-up of patients with primary biliary cholangitis. Clin Liver Dis, 2017, 21(4):709-723. [15]Hirschfield GM, Beuers U, Corpechot C, et al. EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol, 2017, 67(1):145-172. [16]Harms MH, Lammers WJ, Thorburn D, et al. Major hepatic complications in ursodeoxycholic acid-treated patients with primary biliary cholangitis: risk factors and time trends in incidence and outcome. Am J Gastroenterol, 2018, 113(2):254-264. [17]Hao J, Yang T, Zhou Y, et al. Serum metabolomics analysis reveals a distinct metabolic profile of patients with primary biliary cholangitis. Sci Rep, 2017, 7(1):784-794. [18]Mousa HS, Carbone M, Malinverno F, et al. Novel therapeutics for primary biliary cholangitis: Toward a disease-stage-based approach. Autoimmun Rev, 2016, 15(9):870-876. [19]Kuno T, Hirayama-Kurogi M, Ito S, et al. Effect of intestinal flora on protein expression of drug-metabolizing enzymes and transporters in the liver and kidney of germ-free and antibiotics-treated mice. Mol Pharm, 2016, 13(8):2691-2701. [20]Tian F, Chi F, Wang G, et al. Lactobacillus rhamnosus CCFM1107 treatment ameliorates alcohol-induced liver injury in a mouse model of chronic alcohol feeding. J Microbiol, 2015, 53(12):856-863. |